-
Je něco špatně v tomto záznamu ?
N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation
P. Chytil, T. Etrych, J. Kříž, V. Subr, K. Ulbrich,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- akrylamidy chemie MeSH
- doxorubicin chemie farmakologie MeSH
- kinetika MeSH
- koncentrace vodíkových iontů MeSH
- lékové transportní systémy metody MeSH
- molekulární struktura MeSH
- monoklonální protilátky MeSH
- nosiče léků chemie MeSH
- polymerizace MeSH
- protinádorová antibiotika chemie farmakologie MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Controlled radical reversible addition-fragmentation chain transfer (RAFT) polymerisation was used to prepare water-soluble polymer-drug carriers based on copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) with a hydrazide group-containing monomer, showing well-defined structure with narrow molecular weight distribution (approx. 1.1-1.2). The anticancer therapeutic doxorubicin was bound to the polymeric carrier by a hydrazone bond, enabling pH-controlled release under mildly acid conditions that mimics the environment in endosomes/lysosomes of tumour cells. RAFT polymerisation facilitated the synthesis of semitelechelic copolymers, which were used in the synthesis of monoclonal anti-CD20 antibody-polymer-drug conjugate designed for cell-specific tumour targeting. They were also used for producing a biodegradable high-molecular-weight graft polymer-drug conjugate that degrade in the presence of glutathione, which is designed for passive targeting to solid tumours. The conjugates exhibited well-defined structures with narrow molecular weight distributions of approx. 1.3 and pH-controlled drug release.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026864
- 003
- CZ-PrNML
- 005
- 20160318074809.0
- 007
- ta
- 008
- 120816s2010 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejps.2010.08.003 $2 doi
- 035 __
- $a (PubMed)20696244
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Chytil, Petr $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, 162 06 Prague 6, Czech Republic. chytil@imc.cas.cz $7 _AN032430
- 245 10
- $a N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation / $c P. Chytil, T. Etrych, J. Kříž, V. Subr, K. Ulbrich,
- 520 9_
- $a Controlled radical reversible addition-fragmentation chain transfer (RAFT) polymerisation was used to prepare water-soluble polymer-drug carriers based on copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) with a hydrazide group-containing monomer, showing well-defined structure with narrow molecular weight distribution (approx. 1.1-1.2). The anticancer therapeutic doxorubicin was bound to the polymeric carrier by a hydrazone bond, enabling pH-controlled release under mildly acid conditions that mimics the environment in endosomes/lysosomes of tumour cells. RAFT polymerisation facilitated the synthesis of semitelechelic copolymers, which were used in the synthesis of monoclonal anti-CD20 antibody-polymer-drug conjugate designed for cell-specific tumour targeting. They were also used for producing a biodegradable high-molecular-weight graft polymer-drug conjugate that degrade in the presence of glutathione, which is designed for passive targeting to solid tumours. The conjugates exhibited well-defined structures with narrow molecular weight distributions of approx. 1.3 and pH-controlled drug release.
- 650 _2
- $a akrylamidy $x chemie $7 D000178
- 650 _2
- $a protinádorová antibiotika $x chemie $x farmakologie $7 D000903
- 650 _2
- $a monoklonální protilátky $7 D000911
- 650 _2
- $a doxorubicin $x chemie $x farmakologie $7 D004317
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a lékové transportní systémy $x metody $7 D016503
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a polymerizace $7 D058105
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Etrych, Tomáš $7 xx0068504
- 700 1_
- $a Kříž, Jaroslav, $d 1939- $7 xx0003977
- 700 1_
- $a Šubr, Vladimír, $d 1957- $7 xx0088449
- 700 1_
- $a Ulbrich, Karel, $d 1947- $7 jo2004259877
- 773 0_
- $w MED00001639 $t European journal of pharmaceutical sciences official journal of the European Federation for Pharmaceutical Sciences $x 1879-0720 $g Roč. 41, č. 3-4 (2010), s. 473-482
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20696244 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160318074831 $b ABA008
- 999 __
- $a ok $b bmc $g 948906 $s 784210
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 41 $c 3-4 $d 473-482 $e 20100807 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
- LZP __
- $b NLK113 $a Pubmed-20120816/11/01